Allergan (AGN) says Darpin data does not support Phase 3 trials.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
UPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: Amgen Vectibix promotional video found false or misleading
- AvePoint to join S&P SmallCap 600, replacing LXP Industrial Trust
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
